Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Amikacin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Valeo Pharma has recently received a Notice of Compliance from Health Canada granting market authorization for Amikacin, an antibiotic used within the hospital setting. Valeo also announced that shipments of Ethacrynate Sodium have commenced in the U.S. market.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Egrifta
Therapeutic Area: Infections and Infectious Diseases Product Name: F8
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Details:
This new formulation, known as “F8”, is stable at room temperature for up to seven days after reconstitution and its volume of administration is only 0.16 mL making it possible to have a single multidose vial containing seven days of treatment.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
